LITS (Lite Strategy) EBITDA Margin %: 0.00% (As of Mar. 2026)

What is Lite Strategy EBITDA Margin %?

Lite Strategy LITS -3.50% 22 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates LITS with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Lite Strategy ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lite Strategy's EBITDA for the three months ended in Mar. 2026 was $-2.77 Mil. Lite Strategy's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Lite Strategy's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Lite Strategy (NAS:LITS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Lite Strategy EBITDA Margin % Related Terms

Lite Strategy EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Lite Strategy's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lite Strategy EBITDA Margin % Chart

Lite Strategy Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

EBITDA Margin %

Get a 7-Day Free Trial

-172.83

-184.68

-74.52

39.55

0.00

Lite Strategy Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

LITS vs DARE, ALGS, TVGN: EBITDA Margin % Comparison

For the Biotechnology subindustry, Lite Strategy's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lite Strategy EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lite Strategy's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Lite Strategy's EBITDA Margin % falls into.

Save Embed

22GF Score

Lite Strategy Inc LITS

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Lite Strategy EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Lite Strategy's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2025 )	/	Revenue (A: Jun. 2025 )
	=	-17.087	/	0
	=	%

Lite Strategy's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-2.765	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

Lite Strategy (LITS) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lite Strategy and its competitors. According to the industry distribution chart, Lite Strategy ranks #999999 out of 945 companies in the Biotechnology industry.

Is Lite Strategy's EBITDA Margin % too high?

Lite Strategy's current EBITDA Margin % is 0.00%. Based on the distribution chart, Lite Strategy ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lite Strategy has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.

How does Lite Strategy's EBITDA Margin % compare to DARE and ALGS?

According to the Biotechnology industry distribution chart, Lite Strategy ranks #999999 out of 945 companies for EBITDA Margin %. This places Lite Strategy in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lite Strategy and its competitors. Lite Strategy's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Lite Strategy stock overvalued right now?

Lite Strategy (LITS) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Lite Strategy's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Lite Strategy (LITS), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lite Strategy Business Description

Industry Healthcare Biotechnology

Comparable Companies DARE ALGS TVGN BOLD PLRZ ABVC TVRD GRDX INMB APLM VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 0JW9:UK

Address 9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121

Website https://www.litestrategy.com

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

22GF Score

Get the complete analysis for LITS

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.84

Price

View LITS Analysis

See EBITDA Margin % data for all stocks →